No Data
No Data
No Data
Sunshine Nova (688621.SH): Shengpu Pharmaceuticals has accumulated a purchase of 0.35% of the shares.
On July 24th, Gelunhui reported that Yangguang Nuohe (688621.SH) announced that from April 1st, 2024 to July 24th, Shengpu Pharmaceuticals had cumulatively purchased a total of 0.3972 million shares through centralized bidding, accounting for 0.35% of the company's total share capital. The purchase amount was 16 million yuan, and the purchase amount has reached 50% of the planned amount for purchasing company shares.
Yangguang Nuohe (688621.SH): The controlling shareholder Li Qian has lifted the judicial freeze on 0.0338 million shares.
On July 17th, Guosen Securities reported that Sunshine Kaidi New Energy (688621.SH) has received notice that its controlling shareholder, Mr. Li Qian, has released his judicially frozen 33,759 shares. The relevant unfreezing registration procedures have been completed at the China Securities Depository and Clearing Corporation (Shanghai Branch). The reason for the unfreezing is that Mr. Li Qian, the controlling shareholder, provided sufficient funds guarantee and applied to the Beijing Daxing People's Court to lift the share freeze.
Sunshine Kaidi (688621.SH): Liu Yujing's cumulative reduction of 1.35% shareholding.
On July 11th, Geelong reported that Yangguang Nuohe (688621.SH) has received a notification from shareholder Mr. Liu Yujing. Mr. Liu Yujing has reduced his shareholding in the company by 1,516,795 through block trade, accounting for 1.35% of the total share capital of the company. His shareholding percentage has dropped from 5.42% to 4.06%. Mr. Liu Yujing is no longer a shareholder holding more than 5% of the company's shares. As of the disclosure date of this announcement, the above-mentioned shareholding reduction plan has been completed.
Sunshine Novo (688621.SH): STC008 injection received clinical trial approval notice for drug.
On July 11th, Gelunhui announced that its wholly-owned subsidiary Chengdu Nuoheshengtai Biotechnology Co., Ltd. has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The company's research project "STC008 Injection" has been approved for clinical trials. STC008 injection is intended for the treatment of advanced solid tumor cachexia.
Sunshine Kaidi (688621.SH) 2023 annual equity distribution: dividend of 0.165 yuan per share, registered on July 8.
Nuohe Healthcare (688621.SH) has released the annual equity distribution implementation announcement for 2023. This profit distribution is based on...
List of limited unlockings of Zhitong A shares | June 21st
On June 21st, there were a total of 12 listed companies with restricted stocks lifting the ban, with a total market value of about 8.385 billion yuan. The specific situation of restricted stocks lifting the ban today is as follows: Stock Name Stock Code Restricted Stock Type Number of Lifting the Ban Shares Yutong Heavy Industries 600817 stock-based incentive restricted circulation 2.3711 million Kaiyuan Education Technology Group 300338 stock-based incentive restricted circulation 8 million China Leadshine Technology 002979 stock-based incentive restricted circulation 250,000 Shanghai Kelai Mechatronics Engineering 603960 stock-based incentive restricted circulation 592,200 IDT Corp 301315 pre-ipo shares restricted circulation 15 million DBG Technology 300735
No Data